Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 5
1968 11
1969 19
1970 56
1971 141
1972 166
1973 193
1974 194
1975 181
1976 154
1977 179
1978 188
1979 164
1980 178
1981 158
1982 186
1983 173
1984 210
1985 206
1986 220
1987 239
1988 229
1989 296
1990 333
1991 306
1992 264
1993 282
1994 316
1995 312
1996 298
1997 317
1998 314
1999 342
2000 391
2001 393
2002 401
2003 411
2004 453
2005 479
2006 472
2007 515
2008 563
2009 558
2010 648
2011 691
2012 803
2013 836
2014 932
2015 1068
2016 1034
2017 1137
2018 1216
2019 1285
2020 1500
2021 1628
2022 1625
2023 1795
2024 1880
2025 2171
2026 1768

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30,338 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacotherapy: Ketamine and Esketamine.
Feeney A, Papakostas GI. Feeney A, et al. Psychiatr Clin North Am. 2023 Jun;46(2):277-290. doi: 10.1016/j.psc.2023.02.003. Epub 2023 Mar 10. Psychiatr Clin North Am. 2023. PMID: 37149345 Review.
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. ...The long-term safety and efficacy of ketamine/esketamine as antidepressants require further study....
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistan …
Esketamine: Less Drowsiness, More Analgesia.
Mion G, Himmelseher S. Mion G, et al. Anesth Analg. 2024 Jul 1;139(1):78-91. doi: 10.1213/ANE.0000000000006851. Epub 2024 Jan 31. Anesth Analg. 2024. PMID: 38295061 Review.
Racemic ketamine is a 1:1 mixture of 2 enantiomers that turn light in opposite direction: Dextrorotatory esketamine is approximately 4 times more affine for the N-methyl-D-aspartate (NMDA) receptor than levorotatory arketamine, which may explain why esketamine …
Racemic ketamine is a 1:1 mixture of 2 enantiomers that turn light in opposite direction: Dextrorotatory esketamine is approxi …
Long-term safety of ketamine and esketamine in treatment of depression.
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Nikayin S, et al. Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19. Expert Opin Drug Saf. 2022. PMID: 35416105 Review.
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. Here we review what is known about the long-term safety of …
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic …
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Popova V, et al. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.
Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosing. ...The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with trea …
Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosi …
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
Fountoulakis KN, Saitis A, Schatzberg AF. Fountoulakis KN, et al. Am J Psychiatry. 2025 Mar 1;182(3):259-275. doi: 10.1176/appi.ajp.20240515. Epub 2025 Jan 29. Am J Psychiatry. 2025. PMID: 39876682
OBJECTIVE: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. ...These findings need to be considered in light of esketamine's abuse potential and the fact tha …
OBJECTIVE: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with ac …
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA Jr. Bahji A, et al. J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23. J Affect Disord. 2021. PMID: 33022440 Free PMC article.
FINDINGS: 24 trials representing 1877 participants were pooled. Racemic ketamine relative to esketamine demonstrated greater overall response (RR = 3.01 vs. RR = 1.38) and remission rates (RR = 3.70 vs. RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37) …
FINDINGS: 24 trials representing 1877 participants were pooled. Racemic ketamine relative to esketamine demonstrated greater o …
Personalized use of ketamine and esketamine for treatment-resistant depression.
Medeiros GC, Demo I, Goes FS, Zarate CA Jr, Gould TD. Medeiros GC, et al. Transl Psychiatry. 2024 Nov 29;14(1):481. doi: 10.1038/s41398-024-03180-8. Transl Psychiatry. 2024. PMID: 39613748 Free PMC article. Review.
A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression (TRD). Intravenous (R,S)-ketamine (ketamine) and intranasal (S)-ketamine (esketamine) are rapid-ac …
A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression …
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB. Fedgchin M, et al. Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039. Int J Neuropsychopharmacol. 2019. PMID: 31290965 Free PMC article. Clinical Trial.
Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. ...Safety was similar between esketamine/antidepressant groups and no new dose-related safet …
Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 …
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
Bahji A, Zarate CA, Vazquez GH. Bahji A, et al. Expert Opin Drug Saf. 2022 Jun;21(6):853-866. doi: 10.1080/14740338.2022.2047928. Epub 2022 Mar 9. Expert Opin Drug Saf. 2022. PMID: 35231204 Free PMC article.
BACKGROUND: Racemic ketamine and esketamine have demonstrated rapid antidepressant effects. We aimed to review the efficacy and safety of racemic and esketamine for depression. ...CONCLUSIONS: Ketamine and esketamine are effective, safe, and acc …
BACKGROUND: Racemic ketamine and esketamine have demonstrated rapid antidepressant effects. We aimed to review the efficacy an …
The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials.
Hung KC, Kao CL, Ho CN, Hsing CH, Chang YJ, Wang LK, Liao SW, Chen IW. Hung KC, et al. Br J Anaesth. 2024 Jun;132(6):1293-1303. doi: 10.1016/j.bja.2024.03.012. Epub 2024 Apr 12. Br J Anaesth. 2024. PMID: 38614917 Free article.
BACKGROUND: This meta-analysis aimed to evaluate the impact of ketamine/esketamine on postoperative subjective quality of recovery (QoR). METHODS: MEDLINE, Embase, Cochrane library, and Google Scholar were searched for randomised controlled trials (RCTs) that examin …
BACKGROUND: This meta-analysis aimed to evaluate the impact of ketamine/esketamine on postoperative subjective quality of reco …
30,338 results
You have reached the last available page of results. Please see the User Guide for more information.